Management of pancreatic cancer in England
Research type
Research Study
Full title
A longitudinal study exploring the characteristics, treatment pathway, and healthcare resource use of patients with pancreatic cancer in England
IRAS ID
326422
Contact name
Sasha Hazaray
Contact email
Sponsor organisation
Astellas
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Pancreatic cancer is the 10th most common cancer in the UK and has the highest cancer mortality rate worldwide. There is no screening program for pancreatic cancer, and most are diagnosed when the cancer is already at an advanced stage. The only potentially curative treatment for pancreatic cancer is surgery, but this can cause complications and sometimes result in death. For most patients, surgery is often not an effective option and has not been shown to improve survival. While chemotherapy has been shown to improve survival, it is unclear which patient groups most benefit.
This study is a retrospective cohort study using linked registry and administrative data from the National Cancer Registry, including data from the systemic anti-cancer therapy dataset and the radiotherapy dataset, Hospital Episode Statistics, and Office for National Statistics to evaluate the of patients with pancreatic adenocarcinoma (PAC), in England.
In this study, we will include all NCRAS registered individuals 18 years and older with a diagnosis of pancreatic cancer between 1 January 2013 and 31 December 2019 to investigate the treatment, management, survival, and healthcare resource use of patients with PAC.
Outcomes for this study include incidence and prevalence of PAC, PAC overall survival and progression-free survival, number of outpatient visits six months before and after diagnosis by specialty, number of hospital admissions after diagnosis, number of emergency care visits before and after diagnosis, treatment pathway of PAC patients, characteristics of patients who received different drugs as first line treatment for PAC, proportion of cancers with specific biomarkers, proportion of patients tested for biomarkers and timing of test in relation to diagnosis, number of patients with tumour related surgeries or procedures, different types of chemo- and/or radiotherapy, and all-cause health care resource use and associated costs by treatment.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
23/EE/0222
Date of REC Opinion
14 Nov 2023
REC opinion
Further Information Favourable Opinion